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Ischemia reperfusion (I/R) injury refers to the tissue damage which occurs when blood supply returns to tissue after a period
of ischemia and is associated with trauma, stroke, myocardial infarction, and solid organ transplantation. Although the cause
of this injury is multifactorial, increasing experimental evidence suggests an important role for the innate immune system in
initiating the inﬂammatory cascade leading to detrimental/deleterious changes. The Toll-like Receptors (TLRs) play a central role
in innate immunity recognising both pathogen- and damage-associated molecular patterns and have been implicated in a range
of inﬂammatory and autoimmune diseases. In this paper, we summarise the current state of knowledge linking TLR2 and TLR4 to
I/R injury, including recent studies which demonstrate that therapeutic inhibition of TLR2 has beneﬁcial eﬀects on I/R injury in a
murine model of myocardial infarction.
1.Introduction
Our understanding of the molecular components that link
dysregulation of innate immunity and human disease has
led to a plethora of experimental evidence in support of
Toll-like receptors (TLRs) as novel therapeutic targets for a
range of inﬂammatory and autoimmune diseases including
rheumatoid arthritis, systemic lupus erythrematosus (SLE),
multiple sclerosis, inﬂammatory bowel disease, cancer and
diabetes [1].
TLRs, of which there are currently 10 described in
humans, are a family of transmembrane proteins and are
the major pattern recognition receptors (PRRs) binding
to a range of microbial products, often termed pathogen-
associated molecular patterns (PAMPs) [2]. TLR2 functions
as a heterodimer with either TLR1 or TLR6 and senses
lipopeptides from bacteria, with TLR1/2 dimers recognising
triacylatedlipopeptides, TLR2/6,anddiacylatedlipopeptides
[2]. TLR4 binds to LPS from gram negative bacteria, which
is presented to TLR4 by the accessory factor MD2 [2].
TLR4 can also recognise F protein from respiratory syncytial
virusandglycerophosphatidylinositolanchorsfromparasites
and TLR5 binds bacterial ﬂagellin. TLR3 senses double-
stranded RNA, TLR7/8 both recognise single-stranded RNA,
and TLR9 senses CpG-rich hypomethylated DNA [2].
On activation of the receptor, adaptor molecules
(MyD88, MAL, TRIF and TRAM) are recruited to the
receptor through their respective TIR domains, which
interact with the TIR domain of the TLR. This allows
the recruitment and activation of a downstream family of
kinases, IRAKs (IL-1 receptor-associated kinases) 1, 2, and
4. IRAK4 is recruited to the complex ﬁrst, becomes activated,
and phosphorylates IRAK1. These kinases lead to activation
of further downstream kinases, including inhibitor of NF-
κB( I κB) kinases (IKKs), resulting in the release of NF-
κBf r o mI κB, allowing NF-κB to translocate to the nucleus
and mediate an increase in inﬂammatory cytokine gene
expression, leading to pro-inﬂammatory responses [2, 3].
In addition to the recognition of PAMPs, TLR2, TLR4,
and TLR9 have also been shown to recognise endogenous
ligands, which have been termed danger-associated molec-
ular patterns (DAMPs). TLR2 and TLR4 are extracellular
TLRs and have a wide range of putative endogenous ligands
whichincludeheatshockproteins,highmobilitygroupbox1
(HMGB1) and breakdown products of ﬁbronectin, heparan
sulfate, and hyaluronic acid. The broad expression proﬁle of
the TLRs and their ability to recognise many ligands that
are released predominantly as a consequence of injury and
stress positions TLR dependent signaling as a rapid response
mechanism to local tissue damage.2 Mediators of Inﬂammation
2. Ischemia Reperfusion Injury
There is a growing body of evidence linking TLRs, particu-
larly TLR2 and TLR4, to the deleterious inﬂammatory eﬀects
seen in ischemia/reperfusion injury associated with trauma,
stroke, myocardial infarction, and solid organ transplanta-
tion. Ischemia reperfusion injury refers to the tissue damage
caused when blood supply returns to tissue after a period of
ischemia. Cessation of arterial blood ﬂow with immediate
oxygen deprivation of cells (ie, hypoxia with accumulation
of metabolic products) is deﬁned as ischemic injury. Tissue
can be subjected to periods of either cold or warm ischemia
depending on the clinical setting. Cold ischemia occurs
typically in transplantation after organ harvesting and static
cold preservation whilst warm ischemia occurs during
vascular anastomosis or following organ traumas such as
stroke or myocardial infarction. The resistance of various cell
populations to diﬀerent types of ischemia varies depending
on the aﬀected organ, for example, cardiac endothelial cells
are quite resistant to warm ischemia, and major endothelial
injury is only apparent during the reperfusion phase [4]. In
contrast,hepatocytesandKupﬀercellsintheliverandkidney
proximal tubular cells are extremely sensitive to periods
of warm ischemia [5, 6]. Nevertheless organs can tolerate
prolonged cold ischemia periods or short periods of warm
ischemia without signiﬁcant deterioration of function. How-
ever, when ischemia is followed by reperfusion, signiﬁcant
cellular damage is caused [7] which in the case of solid
organ transplantations has been associated with an increased
incidence of delayed graft function (DGF) and primary graft
nonfunction [8, 9].
The absence of oxygen and nutrients from blood creates
a condition in which the restoration of circulation (reperfu-
sion) through the ischemic tissue results in a set of reactions
that can cause injury to vascular and parenchymal cells
[10]. Although the cause of this injury is multi-factorial,
increasing experimental evidence suggests an important role
for the innate immune system in initiating the inﬂammatory
cascade leading to detrimental/deleterious changes. Patho-
logically, reperfusion-induced inﬂammation is characterised
by deposition of complement, upregulation of adhesion
molecules, inﬂammatory cell inﬁltration, and cytokine
release [11–14]. Neutrophils, monocytes and lymphocytes
are the principal immune cells implicated in this process
[15, 16] and facilitate tissue damage through secretion of
proinﬂammatory cytokines, reactive oxygen species, and
chemokines.
3. CardiacIschemia/Reperfusion
Cardiac ischemia/reperfusion is predominantly associated
with myocardial infarction but can also be seen in transplant
and coronary artery bypass graft (CABG) surgery. Early
reperfusion of the ischemic myocardium is a prerequisite
for cardiomyocyte salvage in myocardial infarction. The
shorter the ischemic period, the better the clinical outcome.
Postischemic reperfusion causes deleterious responses in
both cardiomyocytes and circulating cells [17]. Myocardial
I/R (MI/R) injury is the acceleration of both apoptosis
and necrosis of cardiomyocytes at the onset of reperfusion
therapy, resulting in an increase of infarct size, arrhythmias
and contractile dysfunction [18–22]. Current reperfusion
therapy remains suboptimal and necessitates adjunctive
interventions to limit infarct size and enhance clinical out-
come. Experimental studies have clearly demonstrated that
infarct size can be reduced when MI/R injury is prevented
[20, 22].
Reperfusion after myocardial ischemia is a typical
“double-edged sword” that results in disease speciﬁc changes
within cardiomyocytes and circulating cells [23, 24]. The
fact that characteristic pathological changes occur in these
two compartments (parenchymal, i.e., cardiomyocytes ver-
sus. hematopoiesis-derived cells) creates the opportunity to
tackle MI/R injury in two ways; either enhance cardiomy-
ocyte survival and/or disarm deleterious circulating cells.
Interestingly, TLRs are expressed in both compartments;
leukocytes, endothelial cells [25] and cardiomyocytes [26]
express certain TLRs that can have diﬀerent pathophys-
iological consequences for both the host cell as well as
distant organs. Upon ligand binding (either PAMPs or
DAMPs), cardiomyocytes and endothelial cells undergo the
same TLR signal transduction compared to leukocytes. The
main hurdle in MI/R injury is a positive feedback loop
between inﬂammation and cardiomyocyte death: leukocyte-
cardiomyocyte/endothelial cell interaction causes cardiomy-
ocyte death, which in turn releases the same cytokines that
activate and attract leukocytes [24]. Recent studies using
murine MI/R injury models reveal that both TLR2(−/−) and
TLR4(−/−) oﬀer protection from this vicious circle resulting
in a decrease of infarct size and improved cardiac function
[27].
Within the ﬁrst few minutes after reperfusion, NF-κB
translocates to the nucleus to induce pro-inﬂammatory and
proapoptotic gene expression promoting cell dysfunction
and death [24]. Interestingly, experimental data indicate
that parenchymal (i.e. myocardium, endothelium) and cir-
culatory TLR2 are associated with diﬀerent manifestations
of MI/R injury. MI/R injury has four manifestations that
are associated with worse cardiac function and clinical
outcome. Lethal MI/R injury is directly related to cell death
and responsible for infarct size increase during reperfusion.
The so-called “no-reﬂow phenomenon” is the disturbance
of coronary ﬂow in the culprit coronary artery after
reperfusion [28]. Stunning is contractile dysfunction of the
myocardium in the presence of restored coronary ﬂow [29]
and reperfusion associated arrhythmias [30]. Investigators
have observed the diﬀerent manifestations of MI/R injury,
either deliberately or by accident, by using several chal-
lenging experimental methods. TLRs are expressed by both
compartments and therefore the relative contribution of
parenchymal and circulating TLRs to a certain disease entity
requires the use of chimeric mice (WT mice transplanted
with knockout bone marrow and vice versa).
Sakata et al. were among the ﬁrst to show a critical role
for TLR2 in an ex vivo model for MI/R injury [31]. Without
thedetrimentaleﬀectsofbloodcomponents(e.g.leukocytes)
after reperfusion, they showed that infarct size did not diﬀer
between TLR2(−/−) and WT hearts. Nevertheless, contractileMediators of Inﬂammation 3
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Figure 1:Ischemia–reperfusioninjuryischaracterizedbyasublethalinjurytoepithelialcellsresultinginthereleaseofTLRactivatingdanger
signals.Thesedangersignalspromotetheproductionofchemokines,cytokines,oxygenfreeradicalsandtheextravasationofleucocytesfrom
the circulation that ampliﬁes cell damage. Compounds which block TLR activation represent a novel therapeutic mechanism to inhibit this
pro-inﬂammatory cascade thus reducing I/R damage and improving organ function.
performance was signiﬁcantly impaired in WT hearts, and
associated with increased levels of TNFα and IL-1β in the
myocardium. These data indicate that in the presence of
cardiac ischemic injury, loss of cardiac TLR2 signaling is
beneﬁcial for cardiac function. The direct eﬀect of TLR2
activation on contractile performance has been conﬁrmed
in an in vitro setting using a murine cardiomyocyte cell
line. Boyd et al. showed that stimulation of TLR2 resulted
in decreased contractility of plated cardiomyocytes [26].
The ﬁnding that TLR2(−/−) mice have preserved contractile
performancecomparedtoWTmiceinthesettingofS.aureus
induced sepsis, serves as a proof for the link between cardiac
TLR2 activation and depressed cardiac function.
Endothelial dysfunction as seen in “no-reﬂow” seems
to be mediated by both endothelial and circulating TLR2.
Impaired relaxation responses after MI/R injury were
observed in isolated coronary arteries of WT mice and
TLR2(−/−) mice with WT bone marrow [32]. The fact that
both compartments play a role in endothelial dysfunction
after MI/R injury indicates that, indeed, a vicious circle
caused by the interaction of leukocytes and endothelial cells
is critical in MI/R injury-related endothelial dysfunction.
We and others were the ﬁrst to document decreased
infarct size in TLR2(−/−) mice [32, 33]. Using chimeric
TLR2(−/−) mice,weshowedthatcirculatingTLR2completely
mediated TLR2-dependent lethal MI/R injury. Infarct size in
WT mice with TLR2(−/−) bone marrow was similar to that
in complete knockouts. In addition, TLR2(−/−) mice with
WT bone marrow were not protected at all against MI/R
injury, suggesting that parenchymal (i.e. cardiac/endothelial)
TLR2 signaling does not play a role in lethal MI/R injury.
Systemic administration of a TLR2 antagonist just prior
to reperfusion, thus inhibiting circulating TLR2 activation,
decreased infarct size and improved cardiac function via
downregulated inﬂammation and apoptotic signaling in
mice [33].
Ischemic preconditioning (IPC) is a phenomenon in
which brief episodes of repeated ischemia protects the heart
against a more severe and prolonged period of ischemia
and subsequent reperfusion [34]. In line with the above
mentioned ﬁndings, TLR2 also appears to play a pivotal
role in IPC. TLR2(−/−) hearts subjected to MI/R injury did
not beneﬁt from IPC, whereas TLR4(−/−) hearts did show
improved contractile function after IPC and subsequent
MI/R injury [35].
4. Renal Ischemia/Reperfusion
Renal ischemia/reperfusion is most commonly associated
with either trauma or transplant. It is possible to detect
mRNA for all TLRs in human kidney but TLR2 and TLR4
have been the TLRs primarily implicated in mediating renal
ischemia/reperfusion injury. TLR2 and 4 are constitutively
expressed in both proximal and distal tubules, the thin limb
of the loop of Henle and the collecting ducts. Expression
is upregulated in these areas post I/R [36]. Several studies
using TLR2(−/−) and TLR4(−/−) mice have demonstrated
ap r o t e c t i v ee ﬀect in models of renal I/R. Leemans et al.
[37] used both KO mice and antisense oligonucleotides to
show that blockade of TLR2 has a beneﬁcial eﬀect on renal
I/R injury. Following I/R, TLR2(−/−) mice displayed less
tubular epithelial apoptosis, a reduced cellular inﬁltrate and
reduced dysfunction. Through the generation of chimeric
mice, the authors also showed that TLR2 expressed on renal
parenchyma was the key cell type involved in renal tissue
injury which is in contrast to the ﬁndings in myocardial
infarction model where neutrophils and monocytes were
the key cell types mediating injury [33]. Wu et al. [38]
demonstrated up-regulation of TLR4 in tubular epithelial
cells in response to renal I/R and protection against kid-
ney dysfunction in TLR2(−/−) and Myd88(−/−) mice. They
also showed up-regulation of HMGB-1, hyaluronan and4 Mediators of Inﬂammation
brevican, all proposed ligands for TLR2 and TLR4. Pulskens
et al. [39] carried out a similar study using TLR4(−/−)
mice demonstrating a protective eﬀect on renal function,
chemokine production and cellular inﬁltration.
The molecular pathways involved in TLR2-mediated
damage in renal I/R were investigated by Shigeoka et al.
[40]. Using a range of transgenic mice, this study showed
that TLR2(−/−) mice were better protected from I/R damage
than those deﬁcient in MyD88, indicating that pathways
dependent on TLR2 but independent of MyD88 contribute
to kidney injury. More recently Rusai et al. [41]c o m p a r e d
TLR2(−/−) and TLR4(−/−) mice with the double knockout
TLR2/4(−/−) demonstrating protective eﬀects with both
single knock-outs but surprisingly no increased protection
when both TLR2 and TLR4 are deleted. This may indicate
that TLR2 and TLR4 prime each other in the presence of
endogenous ligands, such as during reperfusion injury.
There is also a body of evidence suggesting that TLR2
plays a role in transplantation tolerance. Wang et al.
have demonstrated the important role of TLR and TLR
signalling pathways in the pathogenesis of kidney chronic
allograft dysfunction [42]. In this paper, TLR2 and MyD88,
deﬁciencies signiﬁcantly improved the excretory function
of chronic kidney grafts by 65% and 290% respectively,
and histopathologic signs of chronic allograft damage were
signiﬁcantly ameliorated. T cells, dendritic cells (DCs), and
macrophages were reduced in grafts by up to 4.5-fold and
intragraft concentrations of IL-6, IL-10, monocyte chemo-
tactic protein-1 (MCP-1) and IL-12p70 were signiﬁcantly
lower. In addition TLR2(−/−),M y D 8 8 (−/−),a n dT R I F
(−/−)
deﬁcient recipients showed a signiﬁcant reduction in ﬁbrosis
with collagen I and III levels reduced by up to twofold
compared to wild type mice [42]. These ﬁndings highlight
the functional relevance of TLRs and their two major signal-
ing pathways in graft inﬁltrating in the pathophysiology of
kidney chronic allograft dysfunction.
5. Transplantation
In a cardiac transplantation study, Chen et al. have demon-
strated that TLR2 ligation by the TLR1/2 ligand Pam3CSK4
prevents heart allograft acceptance in mice cotreated with
anti-CD154 costimulation therapy. In contrast, mice receiv-
ing anti-CD154 treatment alone were observed to display
allograft acceptance [43]. In a further study by Jiang et
al., innate immunity-mediated cardiac allograft rejection
was not prevented by cyclosporine A (CsA) treatment [44].
In this study, mice co-treated with CsA and an anti-
inﬂammatory compound called Serp-1 exhibited a signiﬁ-
cantdown-regulationofTLR2andTLR4,reducedgraftinﬁl-
tration of macrophage and T lymphocytes posttransplan-
tation and associated indeﬁnite graft survival. In contrast,
CsA monotherapy did not prevent TLR2 and TLR4 down-
regulation and was ultimately unsuccessful in preventing
graft rejection [44]. Interestingly, the chronic application
of agents such as cyclosporine, which are currently under
investigation in transplant biology, has been associated with
renal injury, which has been correlated with upregulation of
TLR2 expression on renal tubular cells [45]. Furthermore,
increased angiotensin II levels following CsA administration
have also been shown to directly upregulate TLR2 expression
[46].
Delayed Graft Function (DGF) is a frequent consequence
of reperfusion injury of the transplanted donor organ.
Furthermore, organ shortages and increased patient waiting
times for transplants has necessitated the use of extended
criteria and nonheart beating donors. Organs from these
donors are exposed to periods of both warm and cold
ischemia and as such are signiﬁcantly more susceptible to
DGF than organs from heart beating donors which are
only exposed to periods of cold ischemia. Kr¨ uger et al.
[47] looked at expression levels of TLR4 in human kidney
transplants. Whilst TLR4 is constitutively expressed in donor
organs, the level of expression was signiﬁcantly higher in
non-heart beating donor kidneys which also correlated with
increased levels of HMGB-1. They also genotyped the organs
for known TLR4 loss of function mutations which alter
signalling in response to HMGB-1 and other ligands. Those
organs carrying TLR4 mutations exhibited reduced levels
of cytokines and a higher rate of immediate graft function.
This argues that there is a signiﬁcant donor TLR4 eﬀect
contributing to inﬂammation and graft function following
cold ischemia and transplantation. The role of HMGB-1 has
also been explored in a murine model of heart transplant
where administration of a neutralising antibody to HMGB-1
reduced levels of circulating cytokines [48].
Jiang et al. have recently shown that in a rodent model
of liver transplantation the expression of mRNA and protein
of TLR2 and TLR4, CD14 and MD-2 mRNA as well as
endogenous ligands of TLR2 and TLR4 such as HSP60
and HSP70 were quickly and signiﬁcantly increased after
reperfusion, and reached a peak at 3 h after reperfusion. The
appearance of TLR2 and TLR4 mRNA was accompanied by
increasedHSP60and70mRNAwithin24hafterreperfusion
[49]. In addition to these studies, CD14+TLR2+ monocytes
have been demonstrated to be signiﬁcantly upregulated in
patients with acute liver transplant rejection but not in
those with normal liver function post transplantation [50].
Stimulation of TLR2 has also been associated with acute skin
graft rejection in a murine co-stimulation blockade model
where successful skin grafts were observed with anti-CD154
treatment alone but not in the presence of a TLR2 agonist
[51]. In contrast, TLR2-defective animals’ exhibit prolonged
skin graft acceptance [52]. In the latter model, it is worth
noting that it is now well-established that lung, intestine
and skin are more susceptible to acute rejection episodes
posttransplantation than kidney, heart, and pancreas [53].
These studies serve to illustrate further the potential of
TLR2 blockade in solid organ transplantation and predict a
successful outcome in the amelioration of organ dysfunction
post transplant.
6.Other I/RSettings
Several studies have indicated a role for TLR2 in ischemia of
otherorganssuchasbrain[54–56],liver[57–59],bowel[60],
andkidney[36,61–63].Thesestudieshighlightthecomplex-
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Zhangetal.[59],showedthatTLR2mRNAwasincreased
in the ischemic lobes of mice that underwent partial hepatic
I/R. This was associated with an increase in TNF-α in the
portal vein, and was independent of endotoxemia as portal
vein endotoxin did not increase. This indicates a potential
roleforendogenousTLR2ligandsinliverI/R.Shenetal.[58]
used TLR2(−/−) and TLR4(−/−) mice to elucidate the role of
TLRs in liver ischemia. They showed that in warm I/R in the
liver, hepatocellular injury in WT and TLR2(−/−) mice was
equallysevere.ThiswasassociatedwithincreasedTNF-αand
TLR4.However,whenTLR4signalingwasprevented,hepatic
injury was ameliorated and this was associated with reduced
TNF-α levels. There was no eﬀect on expression of TLR2.
These eﬀects appeared to be dependent upon intrahepatic
expression of heme oxygenase 1 (HSP32). The role of HSPs,
in this case HSP72, was further investigated by Galloway
et al. [57]. This study looked at ex vivo hepatocytes from
TLR2 and TLR4(−/−) mice stimulated with HSP72. HSP72
inducedMIP-2inWTcells,thiswasablatedinTLR2(−/−) and
TLR4(−/−) mice. Interestingly, no eﬀect on the concentration
of either IL-6 or TNF was seen. The importance of TLR2 and
TNF-α was also shown by Zhang et al. [64]. However, while
this study showed that a decrease in TNF-α concentration
was beneﬁcial, they also showed that a decrease in TLR2
expression correlated with a beneﬁt on ischemic outcome.
Hui et al. used a model of hepatic I/R and chimeric bone
marrow TLR4(−/−) mice to demonstrate that protective
eﬀects were provided by both parenchymal and circulating
cells [65]. Jin et al. [66] used N-acetylcysteine (NAC) to
prevent the generation of reactive oxygen species (ROS) in
a mouse model of hepatic I/R. They showed that TLR2 and
4 were activated in the liver and lung. It appears that ROS
increases NF-κB activity and causes its translocation to the
nucleus. NAC inhibited the activation of TLR2 and 4, and
the associated induction of TNF-α.
TLR2andTLR4bothappeartoplaycriticalbutopposing
roles in cerebral ischemia. Tang et al. [55] recently showed
that both TLR 2 and 4 are expressed in cerebral cortical
neurons and that selective elimination of their function
suppresses activation of JNK. This protects neurons against
death by energy deprivation and stroke. This indicated that
TLRs also play a role in cerebral ischemia. Ziegler et al. [54]
compared the response of TLR2(−/−) and TLR4(−/−) mice
to cerebral ischemia. They conﬁrmed earlier ﬁndings that
TLR2 is indeed up-regulated in cerebral ischemia. However,
contrary to Hua et al. [67], they showed that TLR2(−/−)
mice had a smaller infarct size. In an earlier study, Hua
et al. [68] showed that preconditioning with Pam3Csk4, a
TLR2 agonist, 24 hours prior to 1 hour of cerebral ischemia
signiﬁcantly reduced brain infarct size, possibly via an eﬀect
on blood brain barrier integrity. In a later study [67], the
same authors used knockout mice to show diﬀerential roles
for TLR2 and TLR4 in cerebral ischemia. This study showed
that brain infarct size was signiﬁcantly less in TLR4(−/−) mice
but was increased in TLR2(−/−) mice. This was associated
with activation of the PI3K/AKT pathway in TLR4(−/−) mice.
ThispathwaywasinhibitedinTLR2(−/−) mice.Thediﬀerence
between this study and that of Ziegler et al. [54]m a yb e
explained by the fact that Zeigler et al., occluded the middle
cerebralartery,whereasHuaetal.[67]occludedthecommon
carotid artery and the internal carotid artery or alternatively
may be a consequence of the diﬀering genetic backgrounds
of the transgenic mice.
7. Conclusions andPerspective
TLRs play complex roles in I/R injuries and the wealth
of data generated using transgenic mice is not always in
agreement. Both TLR2 and TLR4 appear to be key regulators
on the outcome of ischemic damage in many organs. The
relative contribution of parenchymal cells and leukocytes
to I/R injury and subsequent inﬂammation appears to
diﬀer between organs and manifestations of reperfusion
injury. Where double knockouts have been generated, it is
perhaps surprising that there is no synergistic eﬀect where
each single knockout provides improvement in function
and inﬂammation. There are also conﬂicting reports of the
relative importance of Myd88-dependent and -independent
signaling in conferring protection from I/R injury.
The speciﬁc beneﬁt of inhibiting TLR responses appears
to be governed by the organ however it remains to be estab-
lished what the triggers and/or activators are for I/R injury.
From a “danger model” perspective [69], it is postulated that
molecules released during cell stress or cell death may serve
as endogenous ligands for TLRs in ischemia [33]. In essence,
the entire disrupted milieu within apoptotic cells represent
potential candidate ligands when one considers that all
hydrophobic portions (so called “Hyppos”) of molecules
may initiate a danger signal [70]. So far, a few speciﬁc
danger-associated molecules (e.g. HMGB1, HSP60, cardiac
myosin) have been postulated as TLR ligands in ischemia
largely based upon increased levels in damaged tissue but
direct in vivo evidence that these drive the inﬂammatory
response is still lacking. Studies on knockout animals have
been very informative and clearly established a central role
for TLR2 and TLR4 in mediating I/R injury. Nevertheless,
therapeutic intervention studies in both small and large
animal models are required to fully understand the potential
ofTLRsignalingaspharmaceuticaltargets.Thetoolsarenow
available to inhibit TLR2- and TLR4- dependent signaling in
mice as well as neutralizing antibodies to postulated ligands
such as HMGB-1. In addition, further work is required in
other organs such as liver and brain to better understand if
agonism or antagonism is required to confer the beneﬁt.
Recent studies clearly demonstrate that inhibition of
TLR2 has beneﬁcial eﬀects on I/R injury in a murine model
of myocardial infarction [33]o ﬀering the ﬁrst evidence
that therapeutic beneﬁt can be derived from targeting
TLR2. Further studies are required to expand upon these
observations and determine the potential for both TLR2 and
TLR4 antagonists in treating I/R injury in multiple organs.
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